DECISION time for Bayer/Onyx's Nexavar in thyroid cancer
This article was originally published in Scrip
Executive Summary
After a string of Phase III failures in lung cancer, Bayer Healthcare and Onyx Pharmaceuticals' targeted anticancer Nexavar (sorafenib) has met its primary endpoint of improving progression-free survival in a pivotal trial in differentiated thyroid cancer, top-line data show.